Effects of vasopressin on the human non-pregnant uterus: studies with analogues of different vasopressor potencies

Melin, Per; Trojnar, Jerzy; Carlsson, Ann-Mari; Bengtsson, Bengt; Åkerlund, Mats; Robinson, Iain C. A. F.

doi:10.1016/0014-2999(88)90457-8

Cited by 9 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The similarity in responses of a wide variety of myometrial samples to U46619 suggests a number of conclusions. Firstly, although the response to arginine vasopressin varies between endometrial and serosal sections of human non‐pregnant myometrium (Melin et al ., 1988), and the response to PGE 2 varies between top and bottom of the uterus (Wikland et al ., 1984) as well as between different donors (Popat & Crankshaw, 1997), none of these types of variability were seen with U46619 in the present study. This implies that endometrial to serosal, top to bottom and inter‐donor differences are not universal phenomena of agonist‐induced responses of human non‐pregnant myometrium.…”

Section: Discussionmentioning

confidence: 99%

Operational correlates of prostanoid TP receptor expression in human non‐pregnant myometrium are unaffected by excision site or menstrual cycle status of the donor

Senchyna

Crankshaw

1999

British J Pharmacology

View full text Add to dashboard Cite

1 Cumulative concentration-e ect curves for the selective prostanoid TP receptor agonist, U46619, were constructed in strips of human non-pregnant myometrium grouped according to tissue excision site (top, lateral wall, lower uterine segment, sub-serosal or sub-endometrial), tissue orientation (strips cut either parallel or perpendicular to the serosa) and donor menstrual status (proliferative or secretory phase). 2 U46619 was excitatory in all tissues. There was no signi®cant di erence in either pEC 50 or maximum response between groups (P50.05). The range of pEC 50 values was 6.8+0.1 (lateral wall, proliferative phase, n=5) to 7.1+0.3 (lateral wall, secretory phase, n=5). The range of maximum response values was 0.9+0.8 N cm 72 (lateral wall, proliferative phase, n=5) to 3.1+1.0 N cm 72 (lateral wall, secretory phase, n=5). 3 Saturation binding analyses were conducted using the radiolabelled TP receptor agonist, [ 125 I]-BOP. Binding parameters were estimated for membranes prepared from human non-pregnant myometrium excised from the lateral wall and grouped according to donor menstrual status.

show abstract

Section: Discussionmentioning

confidence: 99%

Operational correlates of prostanoid TP receptor expression in human non‐pregnant myometrium are unaffected by excision site or menstrual cycle status of the donor

Senchyna

Crankshaw

1999

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…In randomised order lysine vasopressin (Postacton®, Ferring AB, Sweden) and oxytocin (Syntocinonm, Sandoz AB, Sweden) were then given as intravenous bolus injections over 1 min at a dose of 10pmol/kg body weight. Arginine vasopressin, the human type of vasopressin, is not registered for human use in Sweden, but lysine and arginine vasopressin are equipotent on the human uterus (Melin et al 1988). The recording time after each of these injections was 40 to 45 min.…”

Section: Methodsmentioning

confidence: 99%

“…Details of the membrane preparation techniques have been given previously (Maggi et al 1990, 1992). Previously frozen uterine specimens were first put in one type of buffer (10 mmol/L Tris‐HC1, pH7.4, containing 1.5 mmol/L EDTA, 0.5 mmol/L dithiothreitol, 1 mmol/L benzamidine, 0.01Oh bacitracin, and 0.002% soybean trypsin inhibitor) at 4 °C and homogenised.…”

Section: Methodsmentioning

confidence: 99%

“…As previously described (Maggi et al 1990, 1992), aliquots of membranes (0.3 mg/ml) were incubated with ligands in buffer I1 in the presence of 0.1 % BSA at 22 °C in tubes containing [ 3 H] d (CH 2 ) 5 TyrMe arginine vasopressin (50.7 Ci/mmol; New England Nuclear, Boston, Massachusetts) for 60 min. This vasopressin analogue binds specifically to the vasopressin V1a receptor.…”

Section: Methodsmentioning

confidence: 99%

“…Oxytocin and arginine vasopressin receptors in individual patients were studied using a blocking experimental design in which multiple ligands (labelled ligand, unlabelled ligand and blocking ligand) were present simultaneously in each assay tube (Maggi et al 1990, 1992). Oxytocin sites were studied using homologous competition curves for oxytocin in the presence of 2 nmol/L of d (CH 2 ) 5 TyrMe arginine vasopressin, whereas the vasopressin V1a sites were investigated using homologous competition curves for d(CH 2 ) 5 TyrMe arginine vasopressin blocked by 5 nmol/L oxytocin.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Receptor‐mediated uterine effects of vasopressin and oxytocin in nonpregnant women

Bossmar

Åkerlund

Szamatowicz

et al. 1995

BJOG

Self Cite

View full text Add to dashboard Cite

Objective To study in nonpregnant women myometrial actions of vasopressin and oxytocin and Subjects Twenty-eight women undergoing hysterectomy for benign gynaecological disorders. Interventions Intrauterine pressure recordings. Intravenous bolus injections of 10 pmol/kg body weight of vasopressin and oxytocin. Repeated blood sampling for measurement of vasopressin and oxytocin concentrations in plasma. Recording of effects of vasopressin and oxytocin on isolated myometrium. Estimation of myometrial concentrations of vasopressin V 1 a and oxytocin receptors. Measurement of plasma oestradiol and progesterone. Main outcome measures Vasopressin-and oxytocin-induced increases of the area under the in vivo recording curve over 10 minutes and EC,, concentrations of dose-responses in vitro. Concentrations of vasopressin Vla and oxytocin receptors. ResultsVasopressin was on average four times more potent than oxytocin in vivo. The effect of vasopressin premenstrually was more pronounced than in women under oestrogen influence only (proliferative phase-hyperproliferation; P = 0.02), and tended to be more marked than in those in the luteal phase (P = 0.07). No significant variation in oxytocin response with the hormonal state was observed. EC,, concentrations of vasopressin were more than 20 times lower than those of oxytocin. The median concentration of the vasopressin Vla receptor was 208 (range 139-343) fmol/mg protein and that of the oxytocin receptor 49 (38-87) fmol/mg protein. Vasopressin receptor concentrations and in vivo effects of this peptide did not correlate, whereas for those of oxytocin a significant correlation was observed (P = 0.02). ConclusionThe high potency of vasopressin in nonpregnant women, particularly premenstrually, firmly supports an aetiological importance of this peptide in the uterine hyperactivity of primary dysmenorrhoea. Oxytocin seems to be less important in this condition in view of its much smaller potency and the absence of increase in effect premenstrually. Vasopressin appears to influence both the oxytocin and the vasopressin Vla receptor sites in the uterus, whereas oxytocin acts specifically on its own receptor.

show abstract

Labelling of vasopressin and oxytocin receptors from the human uterus

Tencé

Guillon

Bottari

et al. 1990

European Journal of Pharmacology

View full text Add to dashboard Cite

Effects of vasopressin on the human non-pregnant uterus: studies with analogues of different vasopressor potencies

Cited by 9 publications

References 17 publications

Operational correlates of prostanoid TP receptor expression in human non‐pregnant myometrium are unaffected by excision site or menstrual cycle status of the donor

Operational correlates of prostanoid TP receptor expression in human non‐pregnant myometrium are unaffected by excision site or menstrual cycle status of the donor

Receptor‐mediated uterine effects of vasopressin and oxytocin in nonpregnant women

Labelling of vasopressin and oxytocin receptors from the human uterus

Contact Info

Product

Resources

About